Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle(TM) Platform
MWN-AI** Summary
Cellares and Cabaletta Bio have successfully completed a Technology Adoption Program (TAP) focused on the automated manufacturing of resecabtagene autoleucel (rese-cel), a CAR T cell therapy aimed at treating autoimmune diseases. This partnership underscores Cellares' innovative approach as an Integrated Development and Manufacturing Organization (IDMO), demonstrating their ability to automate processes and reduce costs through their Cell Shuttle™ platform.
Rese-cel is Cabaletta Bio's lead clinical candidate, specifically designed to target CD19 in patients with various autoimmune conditions, including myositis, scleroderma, and lupus nephritis. The TAP validated the feasibility of using the Cell Shuttle to automate the concurrent production of multiple rese-cel batches, indicating readiness for clinical and commercial-scale manufacturing.
The automated manufacturing process addressed every step required, from cell isolation to expansion, ensuring that drug products met quality benchmarks. The success of this program positions Cabaletta Bio to expand rapidly, allowing for global technology transfer to other IDMO Smart Factories, ultimately facilitating faster access to treatment for patients.
Both companies are optimistic about the potential for significant increases in production capacity and the reduction of manufacturing costs, which could enhance their ability to meet the total patient demand. Gwendolyn Binder from Cabaletta expressed enthusiasm for the partnership's potential to deliver curative therapies to more patients, while Cellares CEO Fabian Gerlinghaus highlighted the achievements as encouraging for small biotech collaborations.
Cellares is creating a network of IDMO Smart Factories globally, enabling an efficient scale-up to meet increasing batch demands for cell therapies. Their advanced manufacturing capabilities promise to drive forward the availability of life-changing treatments for autoimmune diseases, benefiting countless patients worldwide.
MWN-AI** Analysis
The recent completion of the Technology Adoption Program (TAP) by Cellares and Cabaletta Bio marks a significant advancement in the automated manufacturing of CAR T cell therapies, specifically the resecabtagene autoleucel (rese-cel) for autoimmune diseases. This groundbreaking collaboration underscores the potential of Cellares’ Cell Shuttle™ platform, a sophisticated system designed to enhance efficiency, lower costs, and provide scalability in cell therapy manufacturing.
With Cellares being the pioneer Integrated Development and Manufacturing Organization (IDMO), their capabilities introduce a new dimension of clinical-grade manufacturing that can significantly reduce the time and investment typically required to meet global demand. The automated nature of the Cell Shuttle™ allows for simultaneous production of multiple rese-cel batches and ensures compliance with cGMP standards, positioning Cabaletta Bio advantageously as they strive to address a considerable patient population affected by autoimmune diseases like myositis, scleroderma, and lupus nephritis.
From a market perspective, the strategic partnership between Cellares and Cabaletta Bio is poised to attract investor interest. As these companies continue to innovate and streamline their operations, they could experience improved funding opportunities and market valuations. Cabaletta Bio’s stock (CABA) might witness volatility depending on the progression of their clinical trials and the successful transition of manufacturing capabilities.
Investors should closely monitor announcements regarding clinical trial results and any updates on the expansion of the Cell Shuttle™ capabilities across new Smart Factories worldwide. The combination of affordable automated manufacturing and the potential therapeutic benefits of rese-cel could lead to substantial long-term returns as both companies establish themselves as leaders in the emerging market for targeted cell therapies. Thus, keeping an eye on the developments from this collaboration will be essential for those looking to capitalize on advancements in biopharmaceuticals.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Technology Adoption Program (TAP) program success demonstrates the ability of Cellares’ IDMO Smart Factory to automate, lower costs and scale out manufacturing for Cabaletta Bio’s clinical-stage CAR T program to treat patients with autoimmune diseases.
Cellares , the first Integrated Development and Manufacturing Organization (IDMO), has concluded the Technology Adoption Program (TAP) on its automated cell therapy manufacturing Cell Shuttle™ for resecabtagene autoleucel, (rese-cel, previously known as CABA-201). Rese-cel is the lead clinical candidate in development by Cabaletta Bio, a biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. This successful collaboration facilitates the opportunity to engage in a clinical and commercial manufacturing relationship.
Cellares’ TAP assessed the feasibility of using Cellares' innovative Cell Shuttle platform to automate the manufacturing of Cabaletta's rese-cel drug product, a CD19-targeting CAR T cell therapy designed to treat patients with a broad range of autoimmune diseases. The TAP successfully delivered automated, concurrent manufacture of multiple rese-cel batches on a single Cell Shuttle. Cabaletta Bio and Cellares are now working towards the goal of manufacturing cGMP cell therapy batches to be delivered to patients. The Cellares network of global IDMO Smart Factories planned for the US, Europe, and Japan has the potential to provide Cabaletta Bio with the ability to automate, lower costs, and scale out manufacturing. Additionally, this partnership may facilitate global expansion of rese-cel via rapid technology transfer to additional IDMO Smart Factories. This has the potential to allow Cabaletta Bio to achieve the global scale required to meet the total patient demand across multiple autoimmune diseases, including myositis (~70,000 patients in the U.S.), scleroderma (~90,000 patients in the U.S.) and lupus nephritis (~100,000 patients in the U.S.), in a fraction of the time and initial investment it would typically take to develop and deliver global supply for these large patient populations.
Cellares’ Cell Shuttle performed all unit operations in an automated manner, including cell isolation, enrichment, gene editing, activation, and expansion. Each unit operation met predefined in-process requirements. The automated process delivered drug products that met pre-defined quality ranges.
"Through our partnership with Cellares, our teams have successfully achieved proof of concept for the ability to automate the rese-cel cellular drug substance manufacturing process. I believe that the potential increase in capacity, meaningful reduction in costs, and rapid global technology transfer offers a potential solution for the global scale out of rese-cel for patients with autoimmune disease,” said Gwendolyn Binder, President, Science and Technology at Cabaletta Bio. “We look forward to continuing our work together to complete activities required to enable use of the Cell Shuttle in clinical trials to support the delivery of these potentially curative autologous therapies to more patients with autoimmune diseases."
"The success of this Technology Adoption Program (TAP) demonstrates the effectiveness of the Cell Shuttle as a scalable, automated, and cost-effective platform for the manufacturing of cell therapies. Working with Cabaletta Bio proves that small biotech companies can successfully partner with Cellares to benefit from next-generation automation," said Fabian Gerlinghaus, CEO of Cellares. “We are excited to contribute to the advancement of rese-cel and the delivery of life-changing therapies to patients worldwide.”
Cellares IDMO Smart Factories allow clients to effectively realize economies of scale even at the low batch numbers required by clients in early clinical development. As clinical development proceeds and the number of batches required grows, the technology allows for the seamless expansion of manufacturing capacity up to commercial volumes of cell therapy batches. These capabilities have the potential to enable Cabaletta Bio to meet the large total global demand from patients with autoimmune disease.
About Cellares
Cellares is the first Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. The company is developing and operating integrated technologies for cell therapy manufacturing to accelerate access to life-saving cell therapies. The company’s Cell Shuttle™ integrates all the technologies required for the entire manufacturing process in a flexible and high-throughput platform that delivers true walk-away, end-to-end automation. While the Cell Shuttle automates cell therapy manufacturing, the Cell Q™ automates quality control both for in-process and release testing. Cell Shuttles™ and Cell Qs™ will be deployed in Cellares’ Smart Factories around the world, enabling each Smart Factory to produce 10 times as many cell therapy batches as a conventional CDMO with the same facility size and headcount. Partnering with Cellares enables early-stage cell therapy developers advantages of immediate, small-volume economies of scale as well as the ability to scale seamlessly to meet the total global patient demand for commercially approved therapies.
The company is headquartered in South San Francisco, California with its first commercial-scale IDMO Smart Factory in Bridgewater, New Jersey. Cellares is building a global network of IDMO Smart Factories with additional facilities under construction in Europe and Japan. The company is backed by world-class investors and has raised over $355 million in financing.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA™ platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of rese-cel, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. Rese-cel is currently being evaluated with a single weight-based dosing regimen across the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. For more information, please visit www.cabalettabio.com and connect with us on LinkedIn.
About rese-cel
Rese-cel is a 4-1BB-containing fully human CD19-CAR T cell investigational therapy for patients with autoimmune diseases where B cells contribute to the initiation and/or maintenance of disease. Following a one-time infusion of a weight-based dose, rese-cel is designed to transiently and deeply deplete all CD19-positive cells in both the peripheral circulation and within tissues. This approach has the potential to reset the immune system and result in profound clinical responses without chronic therapy requirements in patients. Cabaletta is currently evaluating rese-cel in the RESET™ (REstoring SElf-Tolerance) clinical development program which includes multiple disease-specific, company-sponsored clinical trials across expanding portfolios of autoimmune diseases in a broad range of therapeutic areas, including rheumatology, neurology and dermatology.
For more information about Cellares, please visit cellares.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20250319094993/en/
Cellares Contacts
Investors:
ir@cellares.com
Media:
pr@cellares.com
FAQ**
How does the successful completion of the Technology Adoption Program (TAP) impact Cabaletta Bio Inc. CABA’s plans for scaling the manufacturing of rese-cel in response to global patient demand for autoimmune disease treatments?
What specific cost reduction metrics have been observed in the TAP's implementation for Cabaletta Bio Inc. CABA’s CAR T therapy manufacturing process, and how might this influence future investments in the biotechnology sector?
In what ways does the integration of Cellares’ Cell Shuttle technology facilitate the clinical and commercial manufacturing relationship with Cabaletta Bio Inc. CABA?
How might the partnership between Cellares and Cabaletta Bio Inc. CABA enhance the global expansion of rese-cel, and what are the anticipated challenges in achieving rapid technology transfer across the planned IDMO Smart Factories?
**MWN-AI FAQ is based on asking OpenAI questions about Cabaletta Bio Inc. (NASDAQ: CABA).
NASDAQ: CABA
CABA Trading
-6.27% G/L:
$3.065 Last:
867,569 Volume:
$3.20 Open:
